All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1600+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

FDA approves monthly Leqembi (Eisai, Biogen) maintenance dosing for Alzheimer's disease
Monoclonal antibody, Alzheimer’s disease - Read more

Janssen's Lazcluze (EGFR inhibitor) plus Rybrevant (targeting EGFRxMET) approved in Europe for as first-line treatment for EGFR-mutated non-small cell lung cancer
Small molecule, lung cancer, monoclonal antibody - Read more

THE GOOD
Business Development

Nippon Shinyaku pays $36M upfront for US rights to AB2 Bio's rare disease drug tadekinig alfa (IL-8 inhibitor), with $650M in potential milestones
Recombinant protein, autoimmune, hyperinflammatory syndrome, NLRC4 mutation, XIAP deficiency - Read more

Takeda reacquires Japanese rights to depression drug osavampator (AMPA receptor agonist) from Neurocrine Biosciences after initial out-licensing in 2020
Small molecule, depression, major depressive disorder, anhedonia - Read more

PRESENTED BY YOU?
Get the attention of 1600+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE GOOD
Clinical Trials

Sarepta Therapeutics' Elevidys gene therapy delivers positive Ph3 results in Duchenne muscular dystrophy, potentially vindicating last year’s controversial accelerated approval
Gene therapy, Duchenne muscular dystrophy, AAV - Read more

Akero Therapeutics' efruxifermin (targeting FGF21) shows improved fibrosis reduction in Ph2b trial for metabolic dysfunction-associated steatohepatitis with cirrhosis
Fusion protein, metabolic dysfunction-associated steatohepatitis (MASH), liver cirrhosis - Read more

Veru's enobosarm (androgen receptor modulator) combined with Wegovy showed better lean mass preservation in obesity trial versus Wegovy alone
Small molecule, obesity, lean mass preservation, GLP-1 - Read more

Pfizer's Ph3 trial of Braftovi (targeting BRAF V600E mutant) plus cetuximab (targeting EGFR) and mFOLFOX6 shows improved response in BRAF V600E mutated metastatic colorectal cancer patients
Small molecule, colorectal cancer, monoclonal antibody - Read more

⬇️ More Good News ⬇️

THE GOOD
Company Launches

Manas AI launches with $24.6M Seed raise and AI-powered cancer drug discovery ambitions; backed by Pulitzer-winning science author Siddhartha Mukherjee and LinkedIn Co-Founder Reid Hoffman
Small molecule, cancer, drug discovery, AI - Read more

THE GOOD
Earnings & Finances

To Pfizer’s relief, activist investor Starboard Value declines to nominate any board members ahead of Jan. 25 deadline
Activist investor - Read more

THE GOOD
IPOs

Maze Therapeutics plots $131M IPO to fuel kidney disease ambitions
Small molecule, APOL1 kidney disease, chronic kidney disease, phenylketonuria - Read more

Pending lawsuit be damned as Aurion Biotech pursues NYSE listing as "AURN"
Cell therapy, corneal edema, corneal endothelial dysfunction, allogeneic corneal endothelial cells - Read more

Weight-loss company Metsera prices IPO, seeking $289M to support Phase III ambitions
GLP-1, obesity - Read more

THE GOOD
Lawsuits

Hawaii's lawsuit against major pharmacy benefit managers over unfair drug pricing practices survives dismissal attempt in federal court
Pharmacy benefit manager, drug pricing - Read more

Pfizer pays $59.7M settlement over acquisition Biohaven's illegal kickbacks to doctors for prescribing migraine drug Nurtec ODT
Small molecule, migraine, kickbacks - Read more

THE GOOD
Partnerships

Oxford University, GSK launch £50M ($62M) research collaboration to explore potential for preventative cancer vaccines
Cancer vaccine, research partnership - Read more

Agenus seeks pharma partnerships to advance anti-CTLA-4 cancer drug combo after FDA setback
Monoclonal antibody, colorectal cancer - Read more [Paywall]

CStone Pharmaceuticals partners with SteinCares to commercialize cancer drug sugemalimab (anti-PD-L1) across ten Latin American countries
Monoclonal antibody, cancer, solid tumor - Read more

THE GOOD
Public Health

NIH staff can continue research but face restrictions on public communications during Trump administration's temporary freeze on federal agencies
Research funding, public communications - Read more [Paywall]

THE GOOD
Research

Study shows Found's telehealth program achieved significant weight loss using generic drugs and coaching for 66,000 patients
Virtual care, coaching, weight loss, obesity, generic - Read more

Lantern Pharma's AI platform identifies 82 ADC targets and 729 potential payloads for cancer drug development
Antibody-drug conjugate, AI, cancer, drug development, drug discovery - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

THE BAD
Clinical Trials

Allakos discontinues AK006 development after Ph1 trial shows no clinical benefit for chronic spontaneous urticaria patients
Monoclonal antibody, urticaria, hives - Read more

THE BAD
Layoffs

Allakos cuts 75% of workforce after as AK006 (Siglec-6 agonist) flops in Ph1
Monoclonal antibody, urticaria, hives - Read more

Cell therapy biotech Affini-T Therapeutics reportedly conducted layoffs, with former employees posting about job losses on LinkedIn
Cell therapy, cancer, bispecific T-cell engager, autologus TCR-T cell therapy - Read more [Paywall]

THE BAD
Mergers & Acquisition

Sage Therapeutics rejects Biogen's $469 million takeover bid, opts for strategic review to explore better alternatives for shareholders
Small molecule, Alzheimer’s disease, Parkinson’s disease, major depressive disorder - Read more

THE UGLY
Public Health

CDC abruptly halts all collaboration with the WHO, scuttling any hopes of a transition period
Centers for Disease Control & Prevention, World Health Organization, public health, disease outbreaks, infectious disease - Read more [Paywall]

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here